to the editor: Burnette et al. (June 16 issue)1 evaluated bortezomib-based chemotherapy and plasma exchange for the management of myeloma kidney. The reported renal recovery rate of 86% will probably lead to improved patient survival. However, interpretation of these results should be approached with caution.
展开▼
